Newer molecules in the treatment of schizophrenia: A clinical update
Open Access
- 1 January 2011
- journal article
- educational forum
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 43 (2), 105-112
- https://doi.org/10.4103/0253-7613.77334
Abstract
Schizophrenia is a heterogeneous psychiatric disorder in which multiple neurotransmitter systems have been implicated. Increased and decreased dopamine transmission in the subcortical meso-limbic and meso-cortical systems is closely linked to the "positive" and "negative" symptoms of schizophrenia, respectively. Important roles have also been found for serotonin and acetylcholine, both of which are closely linked to dopamine. An abnormality in glutamate functioning involving N-methyl-D-aspartic acid as well as other receptor subtypes may underlie the dopamine dysfunction observed in schizophrenia. Since the discovery of chlorpromazine in 1952, researchers have been developing new molecules targeting various neurotransmitter systems to maximize their efficacy and tolerability. The advancements in molecular genetics have opened up new horizons to manipulate the post-receptor protein cascade and gene expression. Although the magic-wand still eludes us, the newer molecules hold a lot of promise in this condition.Keywords
This publication has 37 references indexed in Scilit:
- Definitions of response and remission in schizophrenia: recommendations for their use and their presentationActa Psychiatrica Scandinavica, 2008
- Restoring GABAergic Signaling and Neuronal Synchrony in SchizophreniaAmerican Journal of Psychiatry, 2008
- Efficacy and Tolerability of Asenapine in Acute SchizophreniaPublished by Physicians Postgraduate Press, Inc ,2007
- Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in SchizophreniaSchizophrenia Bulletin, 2007
- Histamine H3receptor ligands break ground in a remarkable plethora of therapeutic areasExpert Opinion on Investigational Drugs, 2007
- GSK189254, a Novel H3Receptor Antagonist That Binds to Histamine H3Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical ModelsThe Journal of pharmacology and experimental therapeutics, 2007
- COX-2 inhibitors as adjunctive therapy in schizophreniaExpert Opinion on Investigational Drugs, 2004
- SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological ProfileNeuropsychopharmacology, 2003
- Guanfacine Treatment of Cognitive Impairment in SchizophreniaNeuropsychopharmacology, 2001
- Antipsychotic Potential of CCK-Based Treatments: An Assessment Using the Prepulse Inhibition Model of PsychosisNeuropsychopharmacology, 1999